Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention of Nosocomial Pneumonia

NCT05331885 is registered in ClinicalTrials.gov with Aridis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05331885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05331885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Efficacy and Safety of Suvratoxumab in Mechanically Ventilated Adults and Adolescents for the Prevention of Nosocomial Pneumonia
Lead sponsor
Aridis Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
September 2, 2022
Completion date
July 8, 2024
Enrollment
24 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

staphylococcus aureus, ventilator associated pneumonia